Xencor reports Q2 EPS (16c), consensus (19c) Reports Q2 revenue $824K, consensus $1.44M. Based on current operating plans, Xencor expects to have sufficient cash to fund research and development programs and operations through 2016, and maintains the 2014 year-end cash and cash equivalents estimate of approximately $54.0M.
MorphoSys and Xencor publish final results from Phase 1/2a trial of MOR208 MorphoSys and Xencor (XNCR) announced the publication of final results of a Phase 1/2a trial evaluating MOR208 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies. MOR208 was in-licensed by MorphoSys from Xencor in 2010.The results demonstrate that the drug was well tolerated and achieved durable responses in a high risk and poor prognosis patient population with significant progression-free survival achieved.